COVID-19 Drug Producer Reveals Prices, Higher for Privately Insured Americans | Beaufort County Now | Gilead Sciences Inc. revealed Monday its pricing plans for its highly anticipated Covid-19 treatment | daily wire, ben shapiro, coronavirus, covid-19, drug prices, privately insured americans, june 29, 2020

Coronavirus Disease 2019 (COVID-19)

COVID-19 Drug Producer Reveals Prices, Higher for Privately Insured Americans

Publisher's note: This informational nugget was sent to me by Ben Shapiro, who represents the Daily Wire, and since this is one of the most topical news events, it should be published on BCN.

The author of this post is James Barrett.

    Gilead Sciences Inc. revealed Monday its pricing plans for its highly anticipated Covid-19 treatment, remdesivir, including higher prices for Americans with private insurance and lower costs for U.S. government health programs as well as those provided by other developed countries.

    The drugmaker disclosed Monday that it will charge $390 per dose for those on a U.S. government health plan, like Medicare, and $520 per dose - a third more than the government cost - for patients with a private insurance plan.

    For a typical, shorter length treatment (6 doses) those prices amount to $2,340 for those on government plans and $3,120 for those on commercial plans. For a longer course treatment (11 doses), a government plan would cost $4,290 and a privately insured patient would pay $5,720.

    "The drugmaker on Monday disclosed its pricing plans as it prepares to begin charging for the drug in July," The Wall Street Journal reported on Monday. "The U.S. has been distributing remdesivir donated by Gilead since the drug was authorized for emergency use in May."

    In May, after researchers demonstrated that remdesivir shortened the recovery time for patients by an average of four days, the Food and Drug Administration (FDA) officially green-lighted the drug's emergency use for the duration of the crisis. As the Journal noted at the time, "health regulators could grant full approval if more benefits emerge from a large study by the National Institute of Allergy and Infectious Diseases and other clinical trials under way."

    In a statement Monday, Gilead Chief Executive Officer Daniel O'Day said that the company will charge the same $390 per dose for all developed countries. "There is no playbook for how to price a new medicine in a pandemic," said O'Day. The decision to go with one price for most developed countries is an attempt to remove "the need for country by country negotiations on price."

    "The logic is that we wanted a single government price around the developed world," O'Day explained in an interview with the Journal Monday. The pricing is "far below the value it brings to health-care systems and that's true for private payers and government payers," the CEO stressed.

    Gilead appears to be only charging different prices for the drug in the U.S. The choice to provide two different costs in the U.S., the company explained, is a result of the government-specified discounts for many treatments.

    The estimated cost savings of the treatment, said O'Day, should be around $12,000 per patient due to its demonstrated ability to reduce recovery time by an average of four days. The average hospitalization cost per day is around $3,000. A vast majority, 90% to 95%, of those treated with the drug require only a five-day treatment, Gilead's CEO explained.


Latest Op-Ed & Politics

Back in the 15th, 16th, and 17th centuries, church officials felt it necessary to scrutinize every book or pamphlet for the slightest hint of heresy.
On the first day of bill filling, House Majority Leader John Bell (R-Wayne) filed legislation (HB 6) to provide $215 million for the construction of a new Brody School of Medicine facility at East Carolina University.
Editors at Issues and Insights are preparing for a greater crackdown on conservative voices.
Nobody runs for Governor hoping he or she will be confronted with a major disaster while in office. At least we hope not.
With President Biden in the White House and Democrats in control of both houses of Congress, conservatives are bracing for a flurry of policy changes on issues they care about.
Rep. Keith Kidwell will chair the Banking and Finance Committees (Finance is the "tax" committee)
So many families are dealing with it. Someone close to you is troubled to the point that you’re worried about their future.
While an annual report from a financial watchdog shows most U.S. cities are poorly prepared to face the fiscal fallout from the COVID-19 pandemic, the three North Carolina cities examined showed stronger numbers.
The State Board of Elections will hold a remote meeting beginning at 11:00 a.m. on Tuesday, February 23, 2021.


Ghislaine Maxwell is hoping a judge will drop the federal sex-trafficking charges against her thanks to Jeffrey Epstein’s 2007 plea deal, which was supposed to protect himself and his close contacts from sex-trafficking charges.
Sheriff Coleman gives big raises while many taxpayers in Beaufort County are hurting badly
The coronavirus pandemic has created a window of opportunity for school choice, says a panel of experts at a John Locke Foundation Shaftesbury.
The Constitution Party and the Green Party are no longer recognized political parties in North Carolina.
Inez Feltscher Stepman writes for the Federalist about the odd cast of characters engaged in the recent Capitol violence.
Mairead McArdle writes for National Review Online about one high-profile Republican senator’s response to the second impeachment of Donald Trump.
A Texas man who took part in the Capitol riots earlier this month has been hit with new charges related to him allegedly threatening to “assassinate” the radically liberal Congresswoman Alexandria Ocasio-Cortez (D-NY).
Today, America's second Fake Impeachment of Donald J. Trump, just days before he leaves office, may speak more about those Impeaching the President than he who is indicted.


Back to Top